Kanae Gamo is leading overall operations of R&D activities as a CSO. She co-founded FIMECS with her colleagues in 2018 as a curve-out biotech from Takeda Pharmaceutical Company Limited. She started her career at Takeda in 2009. She has expertise in many techniques of molecular biology, genetics, epigenetics and next-generation sequencing in oncology and immunology areas. Through her nine years of pharmaceutical experience at Takeda, she increased responsibility of roles across target identification and validation. In parallel with FIMECS work, she got Ph.D. at the Tsukuba University in 2020. Utilizing proprietary drug discovery platform, RaPPIDS, to internal and collaborative programs, FIMECS seeks to provide life-saving medicine to patients all over the world.